- Home
- ALT vs GOSS Comparison
ALT vs GOSS Comparison
Compare ALT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- GOSS
- Stock Information
- Founded
- ALT 1997
- GOSS 2015
- Country
- ALT United States
- GOSS United States
- Employees
- ALT N/A
- GOSS N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ALT Health Care
- GOSS Health Care
- Exchange
- ALT Nasdaq
- GOSS Nasdaq
- Market Cap
- ALT 292.0M
- GOSS 347.8M
- IPO Year
- ALT N/A
- GOSS 2019
- Fundamental
- Price
- ALT $3.83
- GOSS $2.47
- Analyst Decision
- ALT Strong Buy
- GOSS Strong Buy
- Analyst Count
- ALT 6
- GOSS 4
- Target Price
- ALT $17.40
- GOSS $8.50
- AVG Volume (30 Days)
- ALT 3.0M
- GOSS 3.1M
- Earning Date
- ALT 08-12-2025
- GOSS 08-05-2025
- Dividend Yield
- ALT N/A
- GOSS N/A
- EPS Growth
- ALT N/A
- GOSS N/A
- EPS
- ALT N/A
- GOSS N/A
- Revenue
- ALT $20,000.00
- GOSS $40,237,000.00
- Revenue This Year
- ALT N/A
- GOSS N/A
- Revenue Next Year
- ALT $761,880.20
- GOSS $30.65
- P/E Ratio
- ALT N/A
- GOSS N/A
- Revenue Growth
- ALT N/A
- GOSS N/A
- 52 Week Low
- ALT $2.90
- GOSS $0.66
- 52 Week High
- ALT $11.16
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- ALT 51.79
- GOSS 68.08
- Support Level
- ALT $3.35
- GOSS $2.38
- Resistance Level
- ALT $3.66
- GOSS $2.65
- Average True Range (ATR)
- ALT 0.19
- GOSS 0.15
- MACD
- ALT 0.07
- GOSS 0.03
- Stochastic Oscillator
- ALT 86.18
- GOSS 76.67
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.